<DOC>
	<DOCNO>NCT02327546</DOCNO>
	<brief_summary>The primary purpose study ass single-dose bioavailability AKB-6548 ferrous sulfate relative AKB-6548 healthy volunteer .</brief_summary>
	<brief_title>Effects Ferrous Sulfate Pharmacokinetics AKB-6548</brief_title>
	<detailed_description />
	<criteria>Healthy male subject 18 55 year age body mass index 18 30 kg/m2 Participants partner must use highly effective form contraception study 1 month follow discharge Clinical Research Unit ( CRU ) Subjects must discontinue iron preparation 14 day prior study drug administration Current past history cardiovascular , cerebrovascular , pulmonary , renal liver disease Positive serology result HBsAg , HCV , HIV Screening Renal impairment ( estimate glomerular filtration rate ( eGFR ) &lt; 65mL/min ) Known active cancer ( except nonmelanoma skin cancer ) history chemotherapy use within previous 24 month Current past history gastric duodenal ulcer diseases GI tract ( include gastric bypass surgery ) could interfere absorption study drug Subjects know history smoking and/or use nicotine nicotinecontaining product within past 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Chronic renal insufficiency</keyword>
	<keyword>Renal impairment</keyword>
	<keyword>Ferrous sulfate</keyword>
	<keyword>Iron</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>End stage renal disease</keyword>
	<keyword>Dialysis</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Oral anemia treatment</keyword>
	<keyword>Hypoxia-induciable factor</keyword>
	<keyword>HIF</keyword>
	<keyword>Hypoxia-induciable factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
</DOC>